IRX-5183 is under clinical development by Io Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect IRX-5183’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IRX-5183 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

IRX-5183 overview

IRX-5183 is under development for the treatment of acute myeloid leukemia and multiple myeloma. It is administered orally. The drug candidate is a derivative of vitamin A. Retinoids mediates a number of physiological pathways through their effects on cellular growth and differentiation. It acts by targeting RARalpha. It was also under development for the treatment of solid tumors, acute promyelocytic leukemia and acute myelocytic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms and autoimmune disorders such as encephalomyelitis

Io Therapeutics overview

Io Therapeutics is a biopharmaceutical company that discovers and develops therapeutic compounds. The company develops therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative and auto-immune diseases including multiple sclerosis. Its pipeline products include IRX4204, is an orally available second generation selective RXR agonist against a variety of human cancers in vitro and in animal models including prostate, breast, pancreases and lung; and IRX5183, for the treatment of cancer indications. It offers services in areas of medicinal chemistry and pharmacology. Io Therapeutics is headquartered in Santa Ana, California, the US.

Quick View IRX-5183 LOA Data

Report Segments
  • Innovator
Drug Name
  • IRX-5183
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.